IDEXX Laboratories, Inc. $IDXX Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 43.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,292 shares of the company’s stock after acquiring an additional 993 shares during the quarter. Intech Investment Management LLC’s holdings in IDEXX Laboratories were worth $2,103,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in shares of IDEXX Laboratories by 0.9% during the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after purchasing an additional 86,040 shares during the last quarter. Geode Capital Management LLC grew its stake in IDEXX Laboratories by 2.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,290 shares of the company’s stock worth $1,317,875,000 after buying an additional 54,402 shares during the last quarter. Bank of New York Mellon Corp increased its position in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock worth $1,313,992,000 after buying an additional 605,290 shares during the period. Principal Financial Group Inc. increased its position in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after buying an additional 187,967 shares during the period. Finally, JPMorgan Chase & Co. lifted its stake in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $648.70 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.23 and a quick ratio of 0.90. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $769.98. The business’s 50-day moving average price is $669.92 and its two-hundred day moving average price is $668.75. The company has a market capitalization of $51.65 billion, a P/E ratio of 49.63, a price-to-earnings-growth ratio of 3.86 and a beta of 1.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The firm had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. UBS Group dropped their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a report on Tuesday, February 3rd. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Piper Sandler dropped their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a research note on Monday, February 9th. BTIG Research cut their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Finally, Weiss Ratings lowered IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Seven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Insiders Place Their Bets

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total value of $15,338,011.30. Following the transaction, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $661.54, for a total value of $1,781,527.22. Following the completion of the sale, the executive vice president owned 19,899 shares of the company’s stock, valued at approximately $13,163,984.46. This trade represents a 11.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 44,199 shares of company stock worth $28,746,535 in the last 90 days. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.